Artiva Biotherapeutics awarded President and Head of R&D Miralles Gines Diego 45,000 shares at $0 per share on Sep. 9, 2026. The transaction lifted his reported common-share holding to 122,500 shares, representing about 36.7% of the resulting holding, while a separate award left him with 135,000 derivative securities.

Key Highlights

  • Artiva Biotherapeutics awarded Miralles Gines Diego 45,000 shares at $0 per share on Sep. 9, 2026.
  • Diego owned 122,500 Artiva Biotherapeutics shares after the transaction, representing about 36.7% of his resulting shareholding.
  • A separate award covered 135,000 derivative securities, leaving Diego with 135,000 derivative securities.

Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) awarded President and Head of R&D Miralles Gines Diego 45,000 shares at $0 per share on Sep. 9, 2026. The transaction was recorded under code A, an award or grant classification.

Share Award and Derivative Securities

The award left Diego with 122,500 Artiva Biotherapeutics shares after the transaction. The same date also brought an award of 135,000 derivative securities. Diego’s resulting derivative-securities holding was 135,000. Both transactions carried the A classification, identifying them as awards or grants. The common-share award was issued at $0 per share.

Reported Ownership After the Award

The 45,000-share transaction represented about 36.7% of Diego’s resulting common-share holding. The derivative-securities transaction represented about 100.0% of his resulting derivative-securities holding. Those percentages apply to separate reported holding categories, with 122,500 shares and 135,000 derivative securities shown after the respective transactions.